HEPA Archives - Page 5 of 11

Markets

Cantor starts Hepion Pharma at OW; PT $3.50

Cantor Fitzgerald launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with an “overweight” rating and $3.50 price target. The stock closed at $1.03 on Feb. 25. Hepion’s lead asset, Rencofilstat (CRV431)...

February 28, 2022

Executive Moves

Hepion names world-renowned hepatologist, Dr. Eddie Cheung, to lead strategic medical affairs in Asia

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Eddie Cheung, M.D., FACG, to lead the company’s strategic medical affairs in Asia, a newly-created position. Dr. Cheung will explore and identify possible...

February 15, 2022

Developments

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

Results of a non-clinical research study demonstrated that Hepion Pharmaceuticals’ (NASDAQ:HEPA) clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse...

January 26, 2022

Developments

Rencofilstat adopted as non-proprietary name for Hepion’s CRV431

Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases, CRV431, has been renamed, rencofilstat. The non-proprietary name change was...

January 7, 2022

Developments

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

Dr. Todd Hobbs, CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), will present data from the company’s Phase 2 AMBITION study with drug candidate, CRV431, at the NASH-TAG 2022 conference at Park City, Utah on Jan. 8...

January 5, 2022

Developments

FDA clears Hepion IND for CRV431 in treatment of liver cancer

The FDA accepted Hepion Pharmaceuticals’ (NASDAQ:HEPA) IND application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Liver cancer is the sixth most...

December 21, 2021

Developments

Hepion receives FDA fast track designation for CRV431 to treat NASH

The FDA granted Hepion Pharmaceuticals (NASDAQ:HEPA) fast track designation for its lead drug candidate, CRV431, for the treatment of non-alcoholic steatohepatitis (NASH). CRV431 has been investigated in healthy...

November 30, 2021

Developments

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. In addition...

November 16, 2021

Developments

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, will be...

November 10, 2021

Developments

Hepion Pharma drug-drug-interaction study with CRV431 meets all endpoints

Hepion Pharmaceuticals (NASDAQ:HEPA) met all endpoints in a drug-drug-interaction study with its lead drug candidate, CRV431. The randomized, open label study was conducted in 24 healthy volunteers to determine if...

September 29, 2021

Tag - HEPA

Cantor starts Hepion Pharma at OW; PT $3.50

Hepion names world-renowned hepatologist, Dr. Eddie Cheung, to lead strategic medical affairs in Asia

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

Rencofilstat adopted as non-proprietary name for Hepion’s CRV431

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

FDA clears Hepion IND for CRV431 in treatment of liver cancer

Hepion receives FDA fast track designation for CRV431 to treat NASH

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Hepion Pharma drug-drug-interaction study with CRV431 meets all endpoints

General

More